Post on 27-Mar-2015
Research and Innovation
Research and Innovation
An Overview of European Commission Activities on
Infectious Diseases
Ole OlesenUnit Infectious Diseases and Public Health
Directorate-General for Research and InnovationEuropean Commission
STOA – Aviesan Workshop, Bruxelles – 19 June 2012
PolicyPolicy Research and Innovation
Research and Innovation
The role of the European Commission - Research and innovation
Develop and implement the European research and innovation policy agreed by the European Parliament and European Council.
Funds research through multi-annual framework programmes for research (since 1984).
7th Framework Programme (2007-2013) has a total budget of 53 billion billion € - 4% of the total EU budget.
The European Commission manages about 5% of total public spending in R&D in the European Union.
PolicyPolicy Research and Innovation
Research and Innovation
Total funding: € 53 billion
The 7The 7thth EU Framework Programme (2007- EU Framework Programme (2007-
2013) 2013)
4
EU27
The power of collaboration
PolicyPolicy Research and Innovation
Research and Innovation
Main policy drivers:
Improving health of European citizens
Increasing competitiveness of European health-related industries
Global health issues, incl. emerging epidemics
PolicyPolicy Research and Innovation
Research and Innovation
Objectives for Infectious Diseases in FP7:to improve prevention, diagnostics and treatment of infectious diseases by supporting scientific collaboration between
•Countries•Sectors – public and private
•Area of research
Approximate annual average budget for infectious diseases in FP7: €100 million
PolicyPolicy Research and Innovation
Research and Innovation
Key priorities for infectious diseases in the Health Theme
• Emerging infectious diseases Influenza and other emerging diseases
(incl vector-borne diseases)
• Anti-microbial resistance
• Poverty-related diseases HIV/AIDS, Tuberculosis, malaria
• Neglected Infectious diseases
PolicyPolicy Research and Innovation
Research and Innovation
Distribution in FP7 – so far
Emerging infectious diseases (incl. influenza)Projects: 29 EU contribution: € 141 M
Antimicrobial resistanceProjects: 26 EU contribution: € 131 M
HIV/AIDS, malaria, tuberculosisProjects: 51 EU contribution: € 206 M
Neglected infectious diseases Projects: 15 EU contribution: € 65 M
PolicyPolicy Research and Innovation
Research and Innovation
FP7-funded projectson antimicrobial resistance
• Bacterial infections: 20 projects
• Viral infections: 7 projects
• Protozoan infections: 4 projects
• Fungal infections: 1 project
26 projects in the Health Theme: €131 Mio
“EU Research on Antimicrobial Resistance” presents a selection of these projects:
http://ec.europa.eu/research/health>>Infectious Diseases >>Anti-Microbial Drug Resistance
PolicyPolicy Research and Innovation
Research and Innovation
Co-operation between EU Member States: Joint programming on AMR
• Pulls together national research efforts, uses public resources better, and tackles key common challenges
• Initiative lead by Sweden
• 18 Countries BE, CH, CZ, DE, DK, ES, FI, FR, GR, IL, IT, NL, NO, PL, RO, SE,TK and UK involved
• Only 2 countries (DE and NL) have earmarked programmes for AMR research funding – the others fund AMR research as a result of bottom-up competition.
• Development of a common vision and strategic research agenda – expected this year
• Implementation of joint activities in 2013?
PolicyPolicy Research and Innovation
Research and Innovation
Emerging infectious diseases (including influenza)
29 projects with total EC funding of €141M
16 projects exclusively on human influenza €49M 3 projects on influenza and other emerging pathogens €36M 10 projects on emerging diseases excluding influenza €56M
PolicyPolicy Research and Innovation
Research and Innovation
Disease burden (DALY/year 1000s)
Global prevalence
Annual deaths
58 513 34 million 1.8 million
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, GenevaUNAIDS World AIDS day report, 2011
Key goals in HIV/AIDS research: 18 projects, €84million
• Basic science 3 projects, €1.5M• Drug discovery 3 projects, €8.5M• Vaccines 5 projects,
€32.0M• Microbicides 1 projects,
€12.5M• Diagnostics 2 projects,
€2.0M• Clinical management/treatment 4 projects,
€24.0M• Overarching ERA-NET 1 project, €2.0M
HIV / AIDS
PolicyPolicy Research and Innovation
Research and Innovation
TuberculosisDisease burden (DALY/year 1000s)
Global prevalence
Annual deaths
34 217 13.9 million 1.464 million
Key goals in tuberculosis research: 15 projects, €66 million
• Basic science/host-pathogen interaction 7 projects, €14.5M
• Drug discovery 3 projects, €21.0M• Vaccines 2 projects,
€12.5M• Diagnostics 2 projects,
€6.0M• Clinical management/public health 1 project,
€12.0MWHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.
PolicyPolicy Research and Innovation
Research and Innovation
Disease burden (DALY/year 1000s)
Global prevalence
Annual deaths
33 976 million 889 000
Key goals in malaria research: 18 projects, €56million
• Basic science/host-pathogen interaction 4 projects, €20.3M
• Vector research 5 projects, €20.8M• Drug discovery 3 projects, €4.6M• Vaccines 5 projects,
€7.4M• Diagnostics 1 project,
€2.8M
Malaria
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.
PolicyPolicy Research and Innovation
Research and Innovation
Neglected infectious diseases
Priority disease Disease burden (DALY/year 1000s)
Global prevalence
Annual deaths
Leishmaniasis 1974 12 million 47 000
Sleeping sickness 1673 <100 000 52 000
Chagas disease 430 8-9 million 11 000
Key goals in NID research: 15 projects, €65M
Protozoa (Leishmaniasis, Sleeping sickness, Chagas) Bacteria (Buruli Ulcer, Diarrhoeal diseases) Helminths (Schistosomiasis, Onchocerciasis, Filariasis)
• Basic immunology 5 projects, €13.1M• Vector control/public health 7 projects, €10.5M• Drug discovery 6 projects, €11.0M• Vaccines 7 projects, €25.7M• Diagnostics 3 projects, €4.7M
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.Hotez et al. (2009) Lancet 373:1570-1575.
PolicyPolicy Research and Innovation
Research and Innovation
Collaborative projects improves the European Research Infrastructure
• Consist of 23 beneficiaries from 16 countries + more than 100 collaborating centres
• Access to data from over 250,000 HIV positive people
1616
• Coordinator: Prof. Kholoud Porter, MRC clinical trials unit, London, UK
• EU contribution: € 12 M
• Unique resource
PolicyPolicy Research and Innovation
Research and Innovation
European Developing Countries Clinical Trials Partnership (EDCTP)
• Public-Public Partnership: Joint initiative between 16 Member States and European Commission, established under art. 185
• Independent legal entity (EEIG)
• Coordination of European national programmes for clinical trials in Africa for HIV/AIDS, malaria, TB
• EC contribution of 200 mill Euro + MS contribution of 200 mill Euro
• Launched in 2004, to be renewed 2014 (EDCTP-2)
1717
200 M €
200 M €
PolicyPolicy Research and Innovation
Research and Innovation
Innovative Medicines Initiative (IMI)
• Public-private partnership, initiative under Article 187
• Collaboration between EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a Joint Technology Initiative under FP7
• Objective: to make drug discovery and development more efficient; to bring better medicines faster to patients; and to attract research investment to Europe
• Support / Funding of research activities following open Calls and independent review
1818
PolicyPolicy Research and Innovation
Research and Innovation
Next steps…
• FP7
• Next call for proposals under Health (to be published in July 2012) contains new opportunities for building research infrastructures
• Large Topics (EU contribution up to 24 M Euro) on "Clinical management of patients in severe epidemics"
• Medium-sized topic (EU contribution up to 6 M Euro) on "Drug discovery platform for neglected parasitic diseases"
20 Research and
Innovation
Research and
Innovation
Horizon 2020The EU Framework
Programme for Research and Innovation
2014-2020
THE Future
Research and Innovation
Research and Innovation
Three priorities:1. Excellent science (≈ 30%)
2. Industrial leadership (≈ 30%)
3. Societal challenges (≈ 40%)
Commission has proposed €80 billion budget for 2014-2020
Legislative decision by MS and EP during 2012-2013
Horizon 2020 will start 1 January 2014
PolicyPolicy Research and Innovation
Research and Innovation
Among the Societal Challenges identified :
HEALTH, DEMOGRAPHIC CHANGE
AND WELL-BEING
• How to provide better health, while • maintaining an economically sustainable healthcare system ?
• More health for the money !
PolicyPolicy Research and Innovation
Research and Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered• Effective health promotion and disease
prevention Understanding the determinants of health, improving
health promotion and disease prevention Developing effective screening programmes and
improving the assessment of disease susceptibility Improving surveillance and preparedness of infectious
diseases Developing better preventive vaccines and evidence-
based vaccination schemes
PolicyPolicy Research and Innovation
Research and Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered• Manage, treat and cure diseases and disabilities
Understanding disease Improving diagnosis Using in-silico medicine for improving disease
management and prediction Treating disease Transferring knowledge to clinical practice Individual empowerments for self-management of health
and integrated care
PolicyPolicy Research and Innovation
Research and Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered• Translating research into better healthcare
Better use of health data Improving scientific tools and methods to support policy
making and regulatory needs Active ageing, independent and assisted living Optimising the efficiency and effectiveness of healthcare
systems and reducing inequalities
Research and Innovation
Research and Innovation
Thank you
European CommissionDG Research and InnovationInfectious Diseases and Public Health